Suvorexant for Insomnia: Initiation, Titration, and Safety
Start suvorexant at 10 mg taken once nightly within 30 minutes of bedtime, with at least 7 hours remaining before planned awakening, and increase to a maximum of 20 mg only if the 10 mg dose is well-tolerated but ineffective. 1
Primary Indication
Suvorexant is specifically recommended for sleep maintenance insomnia in adults, though it is FDA-approved for both sleep onset and maintenance difficulties 2, 1. The American Academy of Sleep Medicine (AASM) provides a WEAK recommendation for its use, reflecting low-quality evidence but benefits that outweigh harms 2.
Dosing Algorithm
Standard Initiation
- Starting dose: 10 mg taken once per night 1
- Timing: Within 30 minutes of going to bed
- Minimum sleep opportunity: At least 7 hours remaining before planned awakening
- Critical timing consideration: Avoid taking with or soon after meals, as food delays time to effect by approximately 1.5 hours 1
Titration Strategy
- If 10 mg is well-tolerated but not effective: Increase to 15 mg or 20 mg
- Maximum dose: 20 mg once nightly 1
- Never exceed one dose per night
Special Population Adjustments
Obese women require particular caution before dose escalation 1:
- Obese females have 46% higher AUC and 25% higher Cmax compared to non-obese females 1
- The increased exposure risk should be carefully weighed before increasing from 10 mg
When combined with moderate CYP3A inhibitors 1:
- Start at 5 mg once nightly
- Generally should not exceed 10 mg
- Examples include: diltiazem, verapamil, erythromycin, fluconazole
Strong CYP3A inhibitors: Suvorexant is not recommended with concurrent use of ketoconazole, itraconazole, clarithromycin, ritonavir 1
Absolute Contraindication
Narcolepsy is the only absolute contraindication 1. Suvorexant works by antagonizing orexin receptors (OX1R and OX2R), and loss of orexin signaling is the pathophysiologic basis of narcolepsy 1. Using suvorexant in narcoleptic patients would worsen their underlying condition.
Critical Safety Precautions
CNS Depression and Driving Impairment
- Monitor for next-day somnolence and impaired wakefulness, which may persist for several days after discontinuation 1
- Impairment can occur without subjective symptoms and may not be detected on routine clinical examination 1
- Discontinue or decrease dose if daytime somnolence develops, particularly in patients who drive 1
- Driving ability was objectively impaired in some individuals taking 20 mg in controlled studies 1
High-Risk Populations Requiring Close Monitoring
Depression and suicidal ideation 3:
- Use with caution or close monitoring in patients with depression
- Suicidal ideation has been reported, though rates did not differ significantly from placebo in trials 4
REM sleep behavior disorder risk 3:
- Suvorexant affects REM sleep architecture
- Avoid or closely monitor in patients at risk for REM sleep behavior disorder
Elderly patients:
- No dose adjustment required based on age alone 1
- However, elderly patients may be more susceptible to falls and cognitive effects
Drug Interactions
When combined with other CNS depressants (benzodiazepines, opioids, alcohol, other sedatives):
- Reduce the dose of suvorexant and/or the other CNS depressant due to additive effects 1
- This is a clinical judgment call requiring individualized assessment of sedation risk
Common Adverse Effects
The most frequent adverse event is somnolence 5:
- Number needed to harm (NNH) = 13 for 40/30 mg doses
- NNH = 28 for 20/15 mg doses (approved dose range has even lower risk)
Other common effects (≥5% incidence) include 6, 4:
- Headache
- Dizziness
- Abnormal dreams
- Dry mouth
- Fatigue
Important safety note: Unlike benzodiazepines and Z-drugs, suvorexant showed no rebound insomnia or withdrawal effects when discontinued after 3-12 months of nightly use 5.
Practical Clinical Pearls
Switching from Other Hypnotics
Post-marketing surveillance data suggests that switching directly from another hypnotic to suvorexant (rather than starting as first-line or add-on therapy) is associated with:
- Higher incidence of insomnia-related adverse drug reactions (5.3% vs 0.46% in treatment-naïve patients) 7
- Higher discontinuation rates due to inadequate effect (14.9% vs 9.6%) 7
This likely reflects abrupt discontinuation effects from the prior medication rather than suvorexant itself. Consider tapering the previous hypnotic when switching.
Mechanism Advantage
Unlike GABA-ergic agents (benzodiazepines, Z-drugs), suvorexant preserves natural sleep architecture 8. It prolongs time spent in each sleep stage rather than altering the sleep profile, potentially providing more restorative sleep.
Efficacy Timeline
- Median time to peak concentration: 2 hours (range 30 minutes to 6 hours) 1
- Steady-state achieved by day 3 1
- Mean half-life: approximately 12 hours 1
Comparative Context
While the AASM guideline gives WEAK recommendations to multiple agents (eszopiclone, zolpidem, zaleplon, temazepam, triazolam, ramelteon, doxepin), suvorexant represents a mechanistically distinct option with potentially fewer concerns about tolerance, dependence, and sleep architecture disruption compared to GABA-ergic agents 2, 8. However, head-to-head trials comparing suvorexant directly to other hypnotics are limited, making definitive superiority claims impossible 9, 8.